BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
Number Citing Articles
1 Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV. HCV reinfection incidence among individuals treated for recent infection. J Viral Hepat 2017;24:359-70. [PMID: 28027424 DOI: 10.1111/jvh.12666] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
2 Leung N, Bernacki SE, Bernacki EJ. A Success Story: Advances in Treatment and Lower Disease Prevalence of Hepatitis C Has a Large Impact on Medical Plan Costs. J Occup Environ Med 2019;61:e354-7. [PMID: 31205208 DOI: 10.1097/JOM.0000000000001633] [Reference Citation Analysis]
3 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
5 Marco A, Guerrero RA, Vergara M, Gallego C, Solé C, Planella R, Vaz ME, Teixidó N, Sastre A, Touzón C, da Silva A, Almada G, Ruíz A, Caylà JA, Turu E. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016. Int J Drug Policy 2019;72:189-94. [PMID: 31160156 DOI: 10.1016/j.drugpo.2019.05.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Curr HIV/AIDS Rep 2017;14:110-21. [PMID: 28432579 DOI: 10.1007/s11904-017-0358-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
7 Klepper A, Eng FJ, Doyle EH, El-Shamy A, Rahman AH, Fiel MI, Avino GC, Lee M, Ye F, Roayaie S, Bansal MB, MacDonald MR, Schiano TD, Branch AD. Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Hepatology 2017;66:357-70. [PMID: 27642141 DOI: 10.1002/hep.28846] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
8 Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open 2020;4:964-9. [PMID: 33102771 DOI: 10.1002/jgh3.12376] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res 2018;248:53-62. [PMID: 29477639 DOI: 10.1016/j.virusres.2018.02.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 20.5] [Reference Citation Analysis]
10 Erard-poinsot D, Scholtès C, Billoud C, Zoulim F, Dumortier J. Very late relapse of hepatitis C virus infection immediately after liver transplant. Am J Transplant 2018;18:2587-90. [DOI: 10.1111/ajt.14965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
12 Enokida T, Moreira A, Bhardwaj N. Vaccines for immunoprevention of cancer. J Clin Invest 2021;131:146956. [PMID: 33938446 DOI: 10.1172/JCI146956] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
14 Qian X, Xu C, Wu B, Tang H, Zhao P, Qi Z. SNORD126 Promotes Hepatitis C Virus Infection by Upregulating Claudin-1 via Activation of PI3K-AKT Signaling Pathway. Front Microbiol 2020;11:565590. [PMID: 33042070 DOI: 10.3389/fmicb.2020.565590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zuckerman A, Carver A, Chastain CA. Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes. Curr Treat Options Infect Dis. 2018;10:431-446. [PMID: 30524209 DOI: 10.1007/s40506-018-0177-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
16 Liu CH, Peng CY, Kao WY, Yang SS, Shih YL, Lin CL, Tsai MK, Lee CY, Chang CC, Wu JH, Liu CJ, Su TH, Tseng TC, Chen PJ, Kao JH. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Aliment Pharmacol Ther 2021. [PMID: 34773272 DOI: 10.1111/apt.16697] [Reference Citation Analysis]
17 Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP. Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy. Journal of Hepatology 2017;66:862-3. [DOI: 10.1016/j.jhep.2017.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Luo BF, Rao HY, Gao YH, Wei L. Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study. BMC Public Health 2018;18:708. [PMID: 29879949 DOI: 10.1186/s12889-018-5592-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Goodman S, Zahn M, Bruckner T, Boden-Albala B, Lakon CM. Measuring Hazards of Undetectable Viral Load among Hepatitis C Antibody Positive Residents of a Large Southern California County. Health Serv Res Manag Epidemiol 2021;8:23333928211066181. [PMID: 34926722 DOI: 10.1177/23333928211066181] [Reference Citation Analysis]
20 Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology & Hepatology 2016;1:317-27. [DOI: 10.1016/s2468-1253(16)30075-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
21 Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int 2020;40:51-9. [PMID: 31509639 DOI: 10.1111/liv.14247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. J Int AIDS Soc 2018;21 Suppl 2:e25051. [PMID: 29633559 DOI: 10.1002/jia2.25051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
23 Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. [PMID: 28683982 DOI: 10.1016/j.drugpo.2017.05.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
24 Rademaker M, Agnew K, Anagnostou N, Andrews M, Armour K, Baker C, Foley P, Gebauer K, Gupta M, Marshman G, Rubel D, Sullivan J, Wong LC. Psoriasis and infection. A clinical practice narrative. Australas J Dermatol 2019;60:91-8. [PMID: 30079566 DOI: 10.1111/ajd.12895] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
25 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830 [PMID: 34447228 DOI: 10.3748/wjg.v27.i29.4818] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Grebely J, Dore GJ, Alami NN, Conway B, Dillon JF, Gschwantler M, Felizarta F, Hézode C, Tomasiewicz K, Fredrick LM, Dumas EO, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy 2019;66:73-9. [PMID: 30735896 DOI: 10.1016/j.drugpo.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
27 Martin TCS, Rauch A, Salazar-Vizcaya L, Martin NK. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am 2018;32:395-405. [PMID: 29778262 DOI: 10.1016/j.idc.2018.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS One 2017;12:e0178398. [PMID: 28636638 DOI: 10.1371/journal.pone.0178398] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
29 Chan DP, Sun H, Wong HT, Lee S, Hung C. Sexually acquired hepatitis C virus infection: a review. International Journal of Infectious Diseases 2016;49:47-58. [DOI: 10.1016/j.ijid.2016.05.030] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 12.3] [Reference Citation Analysis]
30 Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Intern Med 2018;57:951-6. [PMID: 29225269 DOI: 10.2169/internalmedicine.9671-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Rivero‐juarez A, Tellez F, Castaño‐carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua‐garcía M, Zapata‐lopez A, Collado A, Gómez‐vidal M, Perez‐stachowski J, Muñoz‐medina L, Fernandez‐fuertes E, Rivero A; on behalf of the Grupo de estudio de Hepatitis virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV ‐infected patients. HIV Med 2019. [DOI: 10.1111/hiv.12715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
33 Nagaty A, Abd El-Wahab EW. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One 2017;12:e0184654. [PMID: 28981513 DOI: 10.1371/journal.pone.0184654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, Ward Z, Vickerman P, Hickman M, Dillon JF. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat 2019;26:519-28. [PMID: 30422370 DOI: 10.1111/jvh.13035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
35 Méndez-Lagares G, Lu D, Chen C, Terrault N, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 2018;200:1124-32. [PMID: 29263212 DOI: 10.4049/jimmunol.1701364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Adu PA, Rossi C, Binka M, Wong S, Wilton J, Wong J, Butt ZA, Bartlett S, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, Velásquez García HA, Krajden M, Janjua NZ. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men. Liver Int 2021;41:482-93. [PMID: 33305525 DOI: 10.1111/liv.14762] [Reference Citation Analysis]
37 Lam JO, Hurley LB, Chamberland S, Champsi JH, Gittleman LC, Korn DG, Lai JB, Quesenberry CP Jr, Ready J, Saxena V, Seo SI, Witt DJ, Silverberg MJ, Marcus JL. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. Int J STD AIDS 2019;30:689-95. [PMID: 31046611 DOI: 10.1177/0956462419836520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Sulkowski MS. The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases 2019;68:577-9. [DOI: 10.1093/cid/ciy551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, Natha M, Zhu Y, Yang J, Kreter B, Brainard DM, Yun C, Carr V, Dore GJ. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Clin Infect Dis. 2016;63:1405-1411. [PMID: 27553375 DOI: 10.1093/cid/ciw580] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 12.5] [Reference Citation Analysis]
40 Cheng CY, Ku SY, Lin YC, Chen CP, Cheng SH, Lin IF. Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV. Viruses 2022;14:439. [PMID: 35216032 DOI: 10.3390/v14020439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Turgeon MK, Lee RM, Gamboa AC, Yopp A, Ryon EL, Goel N, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Maithel SK, Russell MC. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB (Oxford) 2021;23:422-33. [PMID: 32778389 DOI: 10.1016/j.hpb.2020.07.012] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Otero-Romero S, Sánchez-Montalvá A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol 2021;17:285-300. [PMID: 33543657 DOI: 10.1080/1744666X.2021.1886924] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
44 Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019;10:1507. [PMID: 30944315 DOI: 10.1038/s41467-019-09212-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
45 Terrault NA, Hassanein TI. Management of the patient with SVR. Journal of Hepatology 2016;65:S120-9. [DOI: 10.1016/j.jhep.2016.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
46 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52. [PMID: 28288626 DOI: 10.1186/s12916-017-0815-7] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 17.4] [Reference Citation Analysis]
47 Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ;  SIMPLIFY Study Group. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:153-161. [PMID: 29310928 DOI: 10.1016/s2468-1253(17)30404-1] [Cited by in Crossref: 135] [Cited by in F6Publishing: 63] [Article Influence: 33.8] [Reference Citation Analysis]
48 von Köckritz L, Dufour JF. Management of chronic hepatitis C in 2017. Hamostaseologie 2017;37:186-95. [PMID: 27896359 DOI: 10.5482/HAMO-16-07-0019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, Marcotrigiano J, Shoukry NH, Grakoui A. Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells. J Immunol 2016;197:4848-58. [PMID: 27849172 DOI: 10.4049/jimmunol.1600763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
50 Martinello M, Dore GJ, Matthews GV, Grebely J. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infect Dis Clin North Am 2018;32:371-93. [PMID: 29778261 DOI: 10.1016/j.idc.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
51 Domínguez-domínguez L, Bisbal O, Matarranz M, Lagarde M, Pinar Ó, Hernando A, Lumbreras C, Rubio R, Pulido F. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection. Eur J Clin Microbiol Infect Dis 2019;38:725-34. [DOI: 10.1007/s10096-019-03488-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis. PLoS One 2018;13:e0201268. [PMID: 30044871 DOI: 10.1371/journal.pone.0201268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
53 Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine 2019;37:2608-16. [PMID: 30962092 DOI: 10.1016/j.vaccine.2019.02.081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
54 Murdock RM, Brizzi MB, Perez O, Badowski ME. Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review. Infect Dis Ther 2019;8:23-32. [PMID: 30607808 DOI: 10.1007/s40121-018-0228-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
55 Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018;13:e0202109. [PMID: 30114207 DOI: 10.1371/journal.pone.0202109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
56 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
57 Clement ME, Collins LF, Wilder JM, Mugavero M, Barker T, Naggie S. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. Infect Dis Clin North Am 2018;32:407-23. [PMID: 29778263 DOI: 10.1016/j.idc.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
58 Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis. 2016;63:1479-1481. [PMID: 27553377 DOI: 10.1093/cid/ciw579] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
59 Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases 2020;71:1502-10. [DOI: 10.1093/cid/ciz985] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
60 Toyoda H, Yasuda S, Shiota S, Kumada T, Tanaka J. Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy. J Infect Chemother 2021;27:1674-5. [PMID: 34419353 DOI: 10.1016/j.jiac.2021.08.018] [Reference Citation Analysis]
61 Ooka K, Lim JK. Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol 2016;4:206-27. [PMID: 27777889 DOI: 10.14218/JCTH.2016.00017] [Reference Citation Analysis]
62 Yilmaz GR, Boesecke C, Schwarze-Zander C, Rockstroh JK. Hepatitis C reinfection with protease inhibitor-resistant hepatitis C virus in an HIV-coinfected MSM. Liver Int 2020;40:47-50. [PMID: 31612570 DOI: 10.1111/liv.14275] [Reference Citation Analysis]
63 Socías ME, Karamouzian M, Parent S, Barletta J, Bird K, Ti L. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. Int J Drug Policy 2019;72:146-59. [PMID: 31147142 DOI: 10.1016/j.drugpo.2019.05.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
64 Boyer S, Baudoin M, Nishimwe ML, Santos M, Lemoine M, Maradan G, Sylla B, Kouanfack C, Carrieri P, Mourad A, Rouveau N, Moh R, Seydi M, Attia A, Woode ME, Lacombe K. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. BMC Health Serv Res 2022;22. [DOI: 10.1186/s12913-021-07289-0] [Reference Citation Analysis]
65 Aghemo A, Valenti L, Viganò M, Masetti C, Rumi MG, Prati D. Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood? Lancet Haematol 2021;8:e8-e10. [PMID: 33357486 DOI: 10.1016/S2352-3026(20)30402-6] [Reference Citation Analysis]
66 Wong WW, Haines A, Farhang Zangneh H, Shah H. Can we afford not to screen and treat hepatitis C virus infection in Canada? CanLivJ 2018;1:51-65. [DOI: 10.3138/canlivj.1.2.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Elliott T, Cooke GS, Garvey L. Interventions to reduce acute hepatitis C virus in HIV-positive MSM. Curr Opin Infect Dis 2020;33:1-9. [PMID: 31789696 DOI: 10.1097/QCO.0000000000000614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Falade-Nwulia O, Sulkowski M. The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection. J Hepatol 2017;66:267-9. [PMID: 27816493 DOI: 10.1016/j.jhep.2016.10.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
69 Malaguti A, Sani F, Stephens BP, Ahmad F, Dugard P, Dillon JF; ERADICATE-C Study Group. Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships. J Viral Hepat 2019;26:65-72. [PMID: 30260560 DOI: 10.1111/jvh.13009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Girometti N, Devitt E, Phillips J, Nelson M, Whitlock G. High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection. J Viral Hepat 2019;26:627-34. [PMID: 30661272 DOI: 10.1111/jvh.13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Rockstroh JK, Boesecke C. Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men. J Infect Dis 2020;222:S782-8. [PMID: 33245348 DOI: 10.1093/infdis/jiaa096] [Reference Citation Analysis]
72 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
73 Gomez-Escobar E, Burlaud-Gaillard J, Visdeloup C, Silva ARE, Coutant P, Roingeard P, Beaumont E. Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy. Sci Rep 2021;11:21856. [PMID: 34750487 DOI: 10.1038/s41598-021-01428-7] [Reference Citation Analysis]
74 Granozzi B, Guardigni V, Badia L, Rosselli Del Turco E, Zuppiroli A, Tazza B, Malosso P, Pieralli S, Viale P, Verucchi G. Out-of-Hospital Treatment of Hepatitis C Increases Retention in Care among People Who Inject Drugs and Homeless Persons: An Observational Study. J Clin Med 2021;10:4955. [PMID: 34768474 DOI: 10.3390/jcm10214955] [Reference Citation Analysis]
75 Vallet-Pichard A, Pol S. Grazoprevir/elbasvir combination therapy for HCV infection. Therap Adv Gastroenterol 2017;10:155-67. [PMID: 28286567 DOI: 10.1177/1756283X16671293] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
76 Wei L, Huang YH. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther 2019;17:311-25. [PMID: 30856022 DOI: 10.1080/14787210.2019.1588112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
77 Yukawa Y, Tamori A, Iio E, Ogawa S, Yoshida K, Uchida-Kobayashi S, Enomoto M, Tanaka Y, Kawada N. Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse? Clin J Gastroenterol 2019;12:598-602. [PMID: 31165460 DOI: 10.1007/s12328-019-01001-w] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Kurokawa K, Ohki T, Kato J, Fukumura Y, Imai M, Shibata C, Arai J, Kondo M, Takagi K, Kojima K, Seki M, Mori M, Toda N, Tagawa K. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. J Med Case Rep 2020;14:62. [PMID: 32456712 DOI: 10.1186/s13256-020-02392-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Awan AA, Jadoul M, Martin P. Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. Clin Gastroenterol Hepatol 2020;18:2158-67. [PMID: 31376491 DOI: 10.1016/j.cgh.2019.07.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
80 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
81 Konerman MA, Lok AS. Hepatitis C Treatment and Barriers to Eradication. Clin Transl Gastroenterol 2016;7:e193. [PMID: 27657495 DOI: 10.1038/ctg.2016.50] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
82 Zhou HJ, Cao J, Shi H, Naidoo N, Semba S, Wang P, Fan YF, Zhu SC. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front Public Health 2021;9:779215. [DOI: 10.3389/fpubh.2021.779215] [Reference Citation Analysis]
83 Muller A, Vlahov D, Akiyama MJ, Kurth A. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. Int J Environ Res Public Health 2020;17:E4951. [PMID: 32659974 DOI: 10.3390/ijerph17144951] [Reference Citation Analysis]
84 Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
85 Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis 2017;64:1154-62. [PMID: 28199495 DOI: 10.1093/cid/cix126] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
86 Starbird LE, Hong H, Sulkowski MS, Farley JE. Management of the Patient With HIV/Hepatitis C Drug Interactions: A Guide for Nurses and Nurse Practitioners. J Assoc Nurses AIDS Care 2020;31:241-8. [PMID: 31855873 DOI: 10.1097/JNC.0000000000000144] [Reference Citation Analysis]
87 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
88 Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int 2019;39:2244-60. [PMID: 31125496 DOI: 10.1111/liv.14152] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
89 Wansom T, Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moore RD, Thomas DL, Sulkowski MS. Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infect Dis 2017;4:ofx024. [PMID: 28480293 DOI: 10.1093/ofid/ofx024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
90 Olea A Jr, Grochowski J, Luetkemeyer AF, Robb V, Saberi P. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. Integr Pharm Res Pract 2018;7:105-11. [PMID: 30214893 DOI: 10.2147/IPRP.S169282] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Kwok RM, Tran TT. Management of Cirrhotic Patients After Successful HCV Eradication. Curr Treat Options Gastroenterol 2017;15:305-15. [PMID: 28439747 DOI: 10.1007/s11938-017-0134-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
92 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Microbes Infect 2019;21:263-70. [PMID: 31295571 DOI: 10.1016/j.micinf.2019.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
93 Berenguer J, Gil-martin Á, Jarrin I, Montes ML, Domínguez L, Aldámiz-echevarría T, Téllez MJ, Santos I, Troya J, Losa JE, Serrano R, De Guzmán MT, Calvo MJ, González-garcía JJ. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS 2019;33:685-9. [DOI: 10.1097/qad.0000000000002103] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
94 Matičič M, Lombardi A, Mondelli MU, Colombo M; ESCMID Study Group for Viral Hepatitis (ESGVH). Elimination of hepatitis C in Europe: can WHO targets be achieved? Clin Microbiol Infect 2020;26:818-23. [PMID: 31978546 DOI: 10.1016/j.cmi.2020.01.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
95 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15:412-424. [PMID: 29773899 DOI: 10.1038/s41575-018-0026-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
96 Baudoin M, Woode ME, Nishimwe ML, Lemoine M, Sylla B, Kouanfack C, Moh R, Seydi M, Rouveau N, Attia A, Lacombe K, Boyer S. Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa. Liver Int 2020;40:2643-54. [PMID: 32687669 DOI: 10.1111/liv.14613] [Reference Citation Analysis]
97 Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O. HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology 2016;65:S33-45. [DOI: 10.1016/j.jhep.2016.07.012] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 16.8] [Reference Citation Analysis]
98 Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, Darvishian M, Gilbert M, Wong J, Chapinal N, Binka M, Alvarez M, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol 2018;69:1007-14. [PMID: 30142429 DOI: 10.1016/j.jhep.2018.07.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 14.8] [Reference Citation Analysis]
99 O'sullivan M, Jones A, Gage H, Jordan J, Macpepple E, Williams H, Verma S, Dore G. ITTREAT (Integrated Community Test ‐ Stage ‐ TREAT) Hepatitis C service for people who use drugs: Real‐world outcomes. Liver Int 2020;40:1021-31. [DOI: 10.1111/liv.14403] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
100 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
102 Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, Taylor A, Hickman M, Hutchinson S, Vickerman P. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction 2018;113:2118-31. [PMID: 29781207 DOI: 10.1111/add.14267] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
103 Pozza R, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Eradicating hepatitis C virus: The APRN's role. Nurse Pract 2019;44:16-27. [PMID: 31567700 DOI: 10.1097/01.NPR.0000586008.23422.2c] [Reference Citation Analysis]
104 Shin SK, Lee JW, Ra H, Kwon OS, Shin JB, Jin YJ, Lee S, Han KJ, Kim YN, Kim TH, Kim YS, Kim JH. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. J Korean Med Sci 2019;34:e264. [PMID: 31650719 DOI: 10.3346/jkms.2019.34.e264] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Liu C, Liu C, Su T, Tseng T, Chen P, Kao J. Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13302] [Reference Citation Analysis]
106 Kling CE, Limaye AP, Landis CS, Sibulesky L. Expanding access to transplantation with hepatitis C-positive donors: A new perspective on an old issue. Clin Transplant 2017;31. [PMID: 28130837 DOI: 10.1111/ctr.12884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
107 Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020. Kaohsiung J Med Sci 2021;37:7-11. [PMID: 33337581 DOI: 10.1002/kjm2.12345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Rochlani Y, Diab K, Jorde UP. Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities. Curr Heart Fail Rep 2020;17:106-15. [PMID: 32474734 DOI: 10.1007/s11897-020-00466-y] [Reference Citation Analysis]
109 Li Y, Li L, Liu J, Zhang DW, Zhao F, Wang L, Mahemure A, Xie R, Lei S, Cai W, Wang X, Shu Z, Chen X, Wang H, Wang FS. Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China. Hepatol Int 2018;12:465-73. [PMID: 30203381 DOI: 10.1007/s12072-018-9891-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
110 Kuriry H, Casey J, Krassenburg L, La D, Kuczynski M, Shah H, Janssen HLA, Hansen BE, Feld JJ. Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. Clin Gastroenterol Hepatol 2021;19:2398-2406.e1. [PMID: 32629131 DOI: 10.1016/j.cgh.2020.06.061] [Reference Citation Analysis]
111 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y, Toyoda H, Kumada T, Hattori M, Katano Y, Goto H. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. J Viral Hepat 2018;25:1446-51. [PMID: 29993164 DOI: 10.1111/jvh.12967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
112 Krsak M, Montague BT, Trowbridge P, Johnson SC, Binswanger IA. Opioid Use and Chronic Infections: The Value of Addressing the Syndemic in Correctional Settings Via Telemedicine Guidance and Broader Use of Long-Acting Medications. J Infect Dis 2020;222:S486-93. [PMID: 32877543 DOI: 10.1093/infdis/jiaa001] [Reference Citation Analysis]
113 Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med 2017;15:217. [PMID: 29249202 DOI: 10.1186/s12916-017-0979-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
114 Han JW, Sung PS, Kim KH, Hong SH, Shin EC, Jun Song M, Park SH. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection. J Infect Dis 2019;220:1290-301. [PMID: 31152667 DOI: 10.1093/infdis/jiz291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
115 Boschi C, Colson P, Tissot-Dupont H, Bernit E, Botta-Fridlund D, Aherfi S. Hepatitis C Virus Relapse 78 Weeks After Completion of Successful Direct-Acting Therapy. Clin Infect Dis 2017;65:1051-3. [PMID: 28510632 DOI: 10.1093/cid/cix457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
116 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Newsum AM, Matser A, Schinkel J, van der Valk M, Brinkman K, van Eeden A, Lauw FN, Rijnders BJA, van de Laar TJW, van de Kerkhof M, Smit C, Boyd A, Arends JE, Prins M; MSM Observational Study of Acute Infection with hepatitis C (MOSAIC) study group. Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis. Clin Infect Dis 2021;73:460-7. [PMID: 32459339 DOI: 10.1093/cid/ciaa645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
118 Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner BJ, Singal AG, Jain MK. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. BMC Med 2017;15:204. [PMID: 29151365 DOI: 10.1186/s12916-017-0969-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
119 Lombardi A, Mondelli MU; ESCMID Study Group for Viral Hepatitis (ESGVH). Hepatitis C: Is eradication possible? Liver Int 2019;39:416-26. [DOI: 10.1111/liv.14011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
120 Corma-Gómez A, Macías J, Merino Muñoz D, Téllez F, Granados R, Morano LE, De Los Santos Gil I, Vera-Méndez FJ, Collado A, Palacios R, Pineda JA. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. J Infect 2019;79:30-5. [PMID: 31100364 DOI: 10.1016/j.jinf.2019.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
121 Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25:220-227. [PMID: 29316030 DOI: 10.1111/jvh.12859] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
122 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
123 Bragg DA, Crowl A, Manlove E. Hepatitis C: A New Era. Prim Care 2017;44:631-42. [PMID: 29132525 DOI: 10.1016/j.pop.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
124 Pisaturo M, Minichini C, Starace M, Caroprese M, Macera M, Brancaccio G, De Pascalis S, Santonicola A, Galeota Lanza A, Zampino R, Cotticelli G, Sagnelli E, Gaeta GB, Coppola N. Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12. Liver Int 2019;39:844-53. [PMID: 30554459 DOI: 10.1111/liv.14025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
125 Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection 2018;46:717-20. [PMID: 29804205 DOI: 10.1007/s15010-018-1158-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
126 Virlogeux V, Berthillon P, Bordes I, Larrat S, Crouy S, Scholtès C, Pradat P, Maynard M, Zoulim F, Leroy V, Chemin I, Trépo C, Petit MA. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy. Clin Res Hepatol Gastroenterol 2018;42:313-8. [PMID: 29551607 DOI: 10.1016/j.clinre.2018.02.002] [Reference Citation Analysis]
127 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
128 Scott N, Mcbryde ES, Thompson A, Doyle JS, Hellard ME. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut 2017;66:1507-15. [DOI: 10.1136/gutjnl-2016-311504] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 15.2] [Reference Citation Analysis]
129 Alimohammadi A, Holeksa J, Parsons R, Yung R, Amiri N, Truong D, Conway B. Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject drugs in Vancouver’s Downtown Eastside. CanLivJ 2018;1:14-33. [DOI: 10.3138/canlivj.1.2.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
130 Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, Mclean E, Trooskin S, Treloar C, Grebely J. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. International Journal of Drug Policy 2019;66:87-93. [DOI: 10.1016/j.drugpo.2019.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
131 Jordovic J, Bojovic K, Simonovic-Babic J, Gasic V, Kotur N, Zukic B, Vukovic M, Pavlovic S, Lazarevic I, Bekic I, Nikolic N, Uroševic A, Mitrovic N, Delic D. Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused By Chronic Hepatitis C. J Med Biochem 2019;38:45-52. [PMID: 30820183 DOI: 10.2478/jomb-2018-0015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Ng A. Oversimplification of the link between hepatitis C treatment and hepatocellular carcinogenesis? Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(21)00145-6. [PMID: 34996738 DOI: 10.1016/j.rgmxen.2021.05.014] [Reference Citation Analysis]
133 Dore GJ. Hepatitis C treatment as prevention among HIV-infected men who have sex with men: Feasible? Hepatology 2016;64:1834-6. [PMID: 27533636 DOI: 10.1002/hep.28784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Gonzalez SA, Fierer DS, Talal AH. Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat. 2017;16:S1-S23. [PMID: 28701904 DOI: 10.1097/adt.0000000000000104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
135 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436-446. [PMID: 31019253 DOI: 10.1038/s41435-019-0066-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
136 Harkness B, Levy M, Evans R, Wenke J. Why is there still hepatitis C transmission in Australian prisons? A case report. Harm Reduct J 2017;14:75. [PMID: 29178927 DOI: 10.1186/s12954-017-0201-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
137 Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol 2017;14:641-51. [DOI: 10.1038/nrgastro.2017.106] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 18.4] [Reference Citation Analysis]
138 Huang CF, Yu ML. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol 2020;26:251-60. [PMID: 32188235 DOI: 10.3350/cmh.2020.0018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
139 Manickam C, Martinot AJ, Jones RA, Varner V, Reeves RK. Hepatic immunopathology during occult hepacivirus re-infection. Virology 2017;512:48-55. [PMID: 28915405 DOI: 10.1016/j.virol.2017.08.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
140 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
141 Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 2018;68:402-11. [PMID: 29080808 DOI: 10.1016/j.jhep.2017.10.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 18.0] [Reference Citation Analysis]
142 Selfridge M, Cunningham EB, Barnett T, Drost A, Gray-Schleihauf C, Guarasci K, Lundgren K, Milne R, Grebely J, Fraser C. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. Int J Drug Policy 2021;96:103418. [PMID: 34538704 DOI: 10.1016/j.drugpo.2021.103418] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Ghisla V, Scherrer AU, Nicca D, Braun DL, Fehr JS. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000-2016: a systematic review and meta-analysis. Infection 2017;45:309-21. [PMID: 28005195 DOI: 10.1007/s15010-016-0975-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
144 Minoyan N, Artenie AA, Zang G, Jutras-Aswad D, Turcotte MÈ, Bruneau J. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs. Am J Prev Med 2020;58:845-53. [PMID: 32444003 DOI: 10.1016/j.amepre.2020.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. J Infect 2019;79:503-12. [PMID: 31629015 DOI: 10.1016/j.jinf.2019.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
146 Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG; VHICS Study Team. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018;5:ofy103. [PMID: 29977962 DOI: 10.1093/ofid/ofy103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
147 Domínguez-Domínguez L, Lagarde M, Bisbal O, Matarranz M, Rubio R, Pulido F. Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38:275-8. [PMID: 31668860 DOI: 10.1016/j.eimc.2019.07.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]
149 Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107-116. [PMID: 28797497 DOI: 10.1016/j.drugpo.2017.07.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 16.4] [Reference Citation Analysis]
150 Rahnemai-Azar AA, Perkins JD, Leca N, Blosser CD, Johnson CK, Morrison SD, Bakthavatsalam R, Limaye AP, Sibulesky L. Unintended Consequences in Use of Increased Risk Donor Kidneys in the New Kidney Allocation Era. Transplant Proc 2018;50:14-9. [PMID: 29407297 DOI: 10.1016/j.transproceed.2017.11.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
151 Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TCS, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, Vickerman P. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis 2016;62:1072-80. [PMID: 26908813 DOI: 10.1093/cid/ciw075] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 16.3] [Reference Citation Analysis]
152 Holeksa J, Magel T, Alimohammadi A, Thiam A, Yung R, Chu L, Truong D, Conway B. Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. Int J Drug Policy 2019;72:177-80. [PMID: 31176594 DOI: 10.1016/j.drugpo.2019.05.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Zeuzem S. [Chronic hepatitis C : Standard treatment and remaining challenges]. Internist (Berl) 2018;59:528-35. [PMID: 29696303 DOI: 10.1007/s00108-018-0429-y] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
154 Phillips C, Schulkind J, O'Sullivan M, Edelman N, Smith HE, Verma S, Jones CJ. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service. J Viral Hepat 2020;27:176-87. [PMID: 31566851 DOI: 10.1111/jvh.13214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
155 Gountas I, Yiasemi I, Kyprianou E, Mina C, Georgiou C, Katsioloudes P, Kouroufexi A, Demetriou A, Xenofontos E, Nikolopoulos G. Planning the hepatitis C virus elimination in Cyprus: A modeling study. World J Gastroenterol 2021; 27(31): 5219-5231 [PMID: 34497446 DOI: 10.3748/wjg.v27.i31.5219] [Reference Citation Analysis]
156 Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study. Hepatol Commun 2021. [PMID: 34729957 DOI: 10.1002/hep4.1826] [Reference Citation Analysis]
157 Powderly WG, Naggie S, Kim AY, Vargas HE, Chung RT, Lok AS. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases 2017;65:1773-5. [DOI: 10.1093/cid/cix620] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
158 Lok AS, Chung RT, Vargas HE, Kim AY, Naggie S, Powderly WG. Comments on cochrane review on direct-acting antivirals for hepatitis C: Lok et al. Hepatology 2017;66:1016-9. [DOI: 10.1002/hep.29366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
159 Ingiliz P, Martin TC, Rodger A, Stellbrink H, Mauss S, Boesecke C, Mandorfer M, Bottero J, Baumgarten A, Bhagani S, Lacombe K, Nelson M, Rockstroh JK. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. Journal of Hepatology 2017;66:282-7. [DOI: 10.1016/j.jhep.2016.09.004] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 20.8] [Reference Citation Analysis]
160 Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME. Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment? Expert Rev Anti Infect Ther 2018;16:411-22. [PMID: 29722275 DOI: 10.1080/14787210.2018.1471355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
161 Le AK, Zhao C, Hoang JK, Tran SA, Chang CY, Jin M, Nguyen NH, Yasukawa LA, Zhang JQ, Weber SC, Garcia G, Nguyen MH. Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response. Aliment Pharmacol Ther 2017;46:605-16. [PMID: 28766727 DOI: 10.1111/apt.14241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
162 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
163 Qin YJ, Sha RC, Feng YC, Huang YC. Comparison of double antigen sandwich and indirect enzyme-linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies. J Clin Lab Anal 2020;34:e23481. [PMID: 33245583 DOI: 10.1002/jcla.23481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Parlati L, Hollande C, Pol S. Treatment of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2020;101578. [PMID: 33272891 DOI: 10.1016/j.clinre.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
165 Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L. Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change. Am J Transplant 2017;17:2863-8. [DOI: 10.1111/ajt.14386] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
166 Goel A, Bhadauria DS, Aggarwal R. Hepatitis C virus infection and chronic renal disease: A review. Indian J Gastroenterol 2018;37:492-503. [PMID: 30560540 DOI: 10.1007/s12664-018-0920-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
167 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology 2020;72:643-57. [DOI: 10.1016/j.jhep.2019.11.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
169 Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis 2018;5:ofy001. [PMID: 29450210 DOI: 10.1093/ofid/ofy001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
170 Roingeard P, Beaumont E. Hepatitis C Vaccine: 10 Good Reasons for Continuing. Hepatology. 2020;71:1845-1850. [PMID: 32060946 DOI: 10.1002/hep.31182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
171 Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. AIDS 2020;34:1347-58. [PMID: 32590433 DOI: 10.1097/QAD.0000000000002562] [Reference Citation Analysis]
172 Su PS, Su CW, Wu SH, Wei TH, Chu CJ, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. J Chin Med Assoc 2021;84:465-71. [PMID: 33871393 DOI: 10.1097/JCMA.0000000000000528] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One 2019;14:e0217964. [PMID: 31170246 DOI: 10.1371/journal.pone.0217964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
174 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
175 Fuentes A, Mardones C, Burgos PI. Understanding the Cryoglobulinemias. Curr Rheumatol Rep. 2019;21:60. [PMID: 31741077 DOI: 10.1007/s11926-019-0859-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
176 Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc Natl Acad Sci U S A 2018;115:E82-91. [PMID: 29255018 DOI: 10.1073/pnas.1718441115] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
177 Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H. Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. Hepatol Res 2018;48:E78-86. [PMID: 28643404 DOI: 10.1111/hepr.12929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]